AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 7490173
Drug: ST200 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST200 at 1 g/die
Trial: 7490173
Drug: ST200 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ST200 at 0.5 g/die
Trial: 2208182
Drug: CQA 206‐291
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CQA 206‐291 (5‐30 mg/day)
Trial: 517068
Drug: Other marketed
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other marketed bronchodilators (clenbuterol, epinephrine, fenoterol, hexoprenaline, isoprenaline, metaproterenol, reproterol, salbutamol)
Trial: 517068
Drug: Terbutaline and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terbutaline and other adrenoceptor agonists
Trial: 517068
Drug: Combined substance
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined substance drug
Trial: 25669730
Drug: Eltoprazine 5
RxNorm normalized name: Eltoprazine
DrugBank: Eltoprazine (DB12883)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltoprazine 5 mg
Trial: 25669730
Drug: Eltoprazine 7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eltoprazine 7.5 mg
Trial: 22424441
Drug: Dexamethasone (1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone (1.0 mg)
Trial: 8690814
Drug: 8 mg
RxNorm normalized name: alloin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 mg ondansetron (oral and intravenous)
Trial: 1947367
Drug: Cefaclor (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefaclor (500 mg tds) for 7 days
Trial: 1947367
Drug: Amoxycillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (500 mg tds) for 7 days
Trial: 6361318
Drug: KS-R1 (ampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KS-R1 (ampicillin rectal suppository) at a dose of 125 mg X 4/day for 7 days
Trial: 6361318
Drug: Oral form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral form of ampicillin (ABPC) at the same dosage of 125 mg X 4/day for 7 days
Trial: 6361318
Drug: KS-R1 (ampicillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: KS-R1 (ampicillin rectal suppository)
Trial: 6361318
Drug: Oral form
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral form of ampicillin (ABPC)
Trial: 28986670
Drug: Erythropoietin (EPO)
RxNorm normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythropoietin (EPO) administered intravenously for three consecutive days
Trial: 28986670
Drug: Methylprednisolone administered
RxNorm normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methylprednisolone administered intravenously for three consecutive days
Trial: 28986670
Drug: Late treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late treatment (>3 days)
Trial: 20406223
Drug: Levofloxacin 1500
RxNorm normalized name: Levofloxacine
DrugBank: Levofloxacin (DB01137)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levofloxacin 1500 mg
Trial: 15102866
Drug: Levofloxacin (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (various doses)
Trial: 15102866
Drug: Levofloxacin (1500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levofloxacin (1500 mg)
Trial: 12066701
Drug: Excite dual‐cured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excite dual‐cured bonding agent self‐activated by an experimental microbrush in combination with MultiLink resin cement
Trial: 12066701
Drug: Excite light‐cured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Excite light‐cured bonding agent in combination with Variolink II resin cement
Trial: 12066701
Drug: One‐step bonding
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One‐step bonding system in combination with Dual Link resin cement
Trial: 16039
Drug: 3 to
RxNorm normalized name: Melquin-3 Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 to 6 mg lorazepam daily for four weeks
Trial: 29670416
Drug: Intravenous Morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous Morphine
Trial: 8519045
Drug: Probucol (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (750 mg or 1000 mg daily)
Trial: 8519045
Drug: Dipyridamole (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dipyridamole (150 mg daily)
Trial: 29847470
Drug: 8% topical
RxNorm normalized name: BPO 8% Topical Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8% topical capsaicin patch
Trial: 23075701
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg twice a day for 7 days (group A)
Trial: 23075701
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg twice a day for 7 days (group B)
Trial: 23075701
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg twice a day for 3 days each week for 2 weeks (group C)
Trial: 12687927
Drug: Drug I
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug I (propafenone, sotalol, disopyramide)
Trial: 12687927
Drug: Drug II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug II (second antiarrhythmic agent)
Trial: 12687927
Drug: Drug III
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug III (amiodarone)
Trial: 12687927
Drug: Long-term amiodarone
RxNorm normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Long-term amiodarone treatment
Trial: 10419086
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil capsules (1.5-1.8 g DHA/d)
Trial: 10419086
Drug: DHA-rich oil
RxNorm normalized name: Ulkenia DHA oil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHA-rich oil capsules (2 months)
Trial: 10419086
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil capsules (2 months)
Trial: 7539874
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin therapy
Trial: 2193119
Drug: 12-week chemohormonal
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week chemohormonal treatment (CMFVP plus AT)
Trial: 2193119
Drug: 36-week chemohormonal
RxNorm normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 36-week chemohormonal treatment (CMFVP)
Trial: 4935627
Drug: Glycyrrhizinic-acid-reduced liquorice
RxNorm normalized name: glycyrrhizinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycyrrhizinic-acid-reduced liquorice 760 mg thrice daily for six weeks
Trial: 28234199
Drug: In-person or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person or Internet formats of administration for SES-SFP with men
Trial: 28234199
Drug: In-person or
RxNorm normalized name: Medicated Pad or Tape
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In-person or Internet formats of administration for SES-SFV with women
Trial: 22089991
Drug: Conventional palpation-guided
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional palpation-guided anatomic landmark injection
Trial: 19558483
Drug: Manual oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual oral brushing plus 0.12% chlorhexidine oral rinse administered twice per day
Trial: 19558483
Drug: Daily manual
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily manual oral brushing and upright feeding positioning
Trial: 11231036
Drug: Repetitive transcranial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repetitive transcranial magnetic stimulation (rTMS) at a frequency of 0.2 Hz and intensity of 90% of motor threshold, delivered in four daily sessions with a train of 70 stimuli over 350 s
Trial: 9406983
Drug: Atenolol 12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 12.5 mg
Trial: 9406983
Drug: Atenolol 37.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 37.5 mg
Trial: 8218987
Drug: Infusion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 0.2 micrograms/kg ceruletide
Trial: 3619095
Drug: 0.86 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.86 mg/kg nalbuphine
Trial: 3619095
Drug: 0.17 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.17 mg/kg butorphanol
Trial: 29048132
Drug: US-guided rhomboid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided rhomboid major muscle injection
Trial: 29048132
Drug: US-guided trapezius
FDA approved: no
EMA approved: no
PMDA approved: no
Description: US-guided trapezius muscle injection
Trial: 23406268
Drug: 4 implants
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 implants
Trial: 23406268
Drug: 6 implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 implants
Trial: 15331798
Drug: Pexelizumab (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab (bolus and infusion)
Trial: 15331798
Drug: Pexelizumab (bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pexelizumab (bolus plus infusion)
Trial: 16960923
Drug: infliximab 5
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: infliximab 5 mg/kg
Trial: 11410193
Drug: infliximab 10
RxNorm normalized name: infliximab 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: infliximab 10 mg/kg
Trial: 9243353
Drug: Desmethylselegiline (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmethylselegiline (10 mg)
Trial: 31755599
Drug: Deep Brain
RxNorm normalized name: pork brain preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deep Brain Stimulation (DBS) of the STN combined with best medical treatment
Trial: 25595527
Drug: Invasive treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Invasive treatment (coronary angiography performed) - 182 patients
Trial: 25595527
Drug: Conservative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conservative treatment (no coronary angiography) - 131 patients
Trial: 21367726
Drug: 23vP administered
RxNorm normalized name: no vaccine administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 23vP administered after priming with 2 doses of PCV7
Trial: 21367726
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of PCV7
Trial: 15449741
Drug: TIVA Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TIVA Propofol (6 mg/kg/h infusion)
Trial: 11445795
Drug: Behavioral, family-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Behavioral, family-based treatment
Trial: 11445795
Drug: Parental involvement
RxNorm normalized name: C.I. direct red 28 parent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Parental involvement in treatment
Trial: 22232050
Drug: Transdermal nicotine
RxNorm normalized name: nicotine Transdermal System
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Transdermal nicotine (15 mg per day)
Trial: 7936334
Drug: FTTCA (Centella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTTCA (Centella asiatica) 30 mg bid
Trial: 7936334
Drug: FTTCA (Centella
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FTTCA (Centella asiatica) 60 mg bid
Trial: 26381165
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin alone
Trial: 26381165
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg piragliatin alone
Trial: 26381165
Drug: 80 mg
RxNorm normalized name: RNA 180 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mg simvastatin and 100 mg piragliatin together
Trial: 24452825
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy with adjunctive systemic amoxicillin and metronidazole (n=19)
Trial: 24452825
Drug: Nonsurgical periodontal
RxNorm normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nonsurgical periodontal therapy (both groups)
Trial: 22673159
Drug: Oral debriefing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral debriefing alone
Trial: 20829150
Drug: Buccal envelope
RxNorm normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buccal envelope flap (control)
Trial: 18164452
Drug: Cognitive behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive behavioral therapy (CBT) for chronic low back pain; specific dosage and duration not mentioned.
Trial: 15880022
Drug: Everolimus (Certican)
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Everolimus (Certican) in combination with reduced-exposure cyclosporine (CsA)
Trial: 12598264
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus saline (MS; n = 114)
Trial: 12598264
Drug: Morphine plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine plus ketamine (MK; n = 131)
Trial: 10367600
Drug: Perindopril (PER),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Perindopril (PER), 2 mg once daily
Trial: 10367600
Drug: Captopril (CAP),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (CAP), 6.25 mg t.i.d.
Trial: 1855277
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg prednimustine
Trial: 29389835
Drug: 4 mg
RxNorm normalized name: lutein 4 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg (oral) SAL
Trial: 29389835
Drug: 800 μg
RxNorm normalized name: hyaluronidase
DrugBank: Hyaluronidase (DB14740)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 800 μg (inhaled) SAL
Trial: 25412911
Drug: Hormonal treatment,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hormonal treatment, Radiotherapy, Operation
Trial: 12810176
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 20 mg weekly for 84 days
Trial: 12810176
Drug: Oral ibandronate
RxNorm normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral ibandronate 2.5 mg daily for 84 days
Trial: 12810176
Drug: Cumulative dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cumulative dose 130 mg or less
Trial: 12810176
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment for 168 days
Trial: 10589647
Drug: IV amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV amino acid mixture, 126 mL/h
Trial: 16415516
Drug: Acetated Ringer's
RxNorm normalized name: ACETATED RINGER'S
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetated Ringer's solution
Trial: 1817629
Drug: Diamorphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 5 mg in 0.9% sodium chloride 8 ml
Trial: 1817629
Drug: Diamorphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diamorphine 5 mg in 0.9% sodium chloride 8 ml with 1:200,000 adrenaline
Trial: 1817629
Drug: 0.375% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine 8 ml
Trial: 7172717
Drug: Topical 2.5%
RxNorm normalized name: menthol topical 2.5% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2.5% phenylephrine hydrochloride
Trial: 30652422
Drug: Ursodeoxycholic acid
RxNorm normalized name: Ursodeoxycholic acid
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ursodeoxycholic acid (UDCA) at 8-10 mg/kg of body weight per day
Trial: 28248693
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg Calcium (CA)
Trial: 27154593
Drug: Avoralstat 250
RxNorm normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat 250 mg single dose
Trial: 27154593
Drug: Avoralstat 800
RxNorm normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat 800 mg multiple doses (q8 h for up to 7 days)
Trial: 27154593
Drug: Avoralstat 2400
RxNorm normalized name: Avoralstat
DrugBank: Avoralstat (DB12120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat 2400 mg/day multiple doses
Trial: 27154593
Drug: Avoralstat (doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Avoralstat (doses ≥400 mg q8 h)
Trial: 1324534
Drug: Low molecular
RxNorm normalized name: Low molecular weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low molecular weight heparin (3,000 anti-Xa units, one subcutaneous injection)
Trial: 1324534
Drug: Low-dose heparin
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose heparin (5,000 U, subcutaneously three times a day)
Trial: 1324534
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups (low molecular weight heparin and low-dose heparin)
Trial: 6383491
Drug: Bestatin 10
RxNorm normalized name: tolnaftate
DrugBank: Tolnaftate (DB00525)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bestatin 10 mg orally three times daily for at least one year
Trial: 6383491
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no further adjuvant treatment)
Trial: 6383491
Drug: Bestatin treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bestatin treatment
Trial: 24135557
Drug: Monthly intravitreal
RxNorm normalized name: Dexamethasone Intravitreal Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monthly intravitreal ranibizumab (0.5 mg) injections
Trial: 19248192
Drug: Pantoprazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole treatment for 3 months
Trial: 19248192
Drug: Pantoprazole treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole treatment for 6 months
Trial: 12478843
Drug: Oral sildenafil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral sildenafil (group A)
Trial: 12478843
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of prostaglandin E1 (PGE1) (group B)
Trial: 12478843
Drug: Intracavernosal injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracavernosal injection of PGE1 (group B)
Trial: 7700741
Drug: RSVIG 750
RxNorm normalized name: RSVIG
DrugBank: Respigam (DB17765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RSVIG 750 mg/kg (high dose)
Trial: 23061828
Drug: High-dose N-acetylcysteine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose N-acetylcysteine (NAC) 1200 mg/daily
Trial: 21813919
Drug: L-carnitine L-tartrate
RxNorm normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine L-tartrate (3 g, 2 g L-carnitine/d; n = 8)
Trial: 19403652
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (tenofovir disoproxil fumarate and efavirenz)
Trial: 19403652
Drug: Three-drug regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three-drug regimen (tenofovir DF, lamivudine, and efavirenz)
Trial: 19403652
Drug: Two-drug regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-drug regimen (tenofovir DF and efavirenz)
Trial: 15022504
Drug: Topical medications
RxNorm normalized name: Procto-Med Topical Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical medications (antifungals or disinfectants)
Trial: 11286949
Drug: Colesevelam 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.8 g
Trial: 11286949
Drug: Colesevelam 3.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 3.8 g with Simvastatin 10 mg
Trial: 11286949
Drug: Colesevelam 2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 2.3 g
Trial: 11286949
Drug: Colesevelam 2.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colesevelam 2.3 g with Simvastatin 20 mg
Trial: 2446091
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high dosage, about 700 mg intravenously from the start of anaesthesia to the end of operation)
Trial: 2446091
Drug: Aprotinin (high
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprotinin (high dosage)
Trial: 22872770
Drug: Prednisolone 30
RxNorm normalized name: prednisolone 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisolone 30 mg/d for 7 days
Trial: 18560140
Drug: Constraint-induced movement
RxNorm normalized name: constant albicans extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Constraint-induced movement therapy (CIMT) with modified opposition restriction orthosis (MORO), 5 hours/day, 7 days/week for 8 weeks
Trial: 15831644
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of DSE improvement or DWT > 0.8 cm
Trial: 19433800
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C (1000 mg/day) and Vitamin E (400 IU/day)